ArticleZeitschrift fur Rheumatologie2025
[Severe late-onset neutropenia after rituximab administration].
Article in Zeitschrift fur Rheumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab (RTX) causes B‑cell depletion by binding to the CD20 antigen. A less well-known adverse drug reaction of RTX is late-onset neutropenia (LON), which occurs approximately 6 months after treatment initiation. As clinical management, regular differential blood cell counts should be performed during RTX treatment. Besides a watch-and-wait strategy, supportive administration of granulocyte colony-stimulating factor (G-CSF) can be discussed for acute LON episodes. Re-exposure to RTX after LON has occurred is generally considered acceptable after diligent benefit-risk evaluation and thorough patient information. In this case series, we would like to present 2 cases of rheumatology patients with severe LON after RTX administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.